Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic Regimens for Grade III Open Fractures
NCT03560232Phase 4Terminated
- Sponsor
- Mercy
- Start
- Jul 2018
- Primary completion
- Feb 2020
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of ceftriaxone, ampicillin + sulbactam, piperacillin + tazobactam in post-operative wound infection (SSI), sponsored by Mercy. Started Jul 2018; status: terminated.
02
Drugs
ceftriaxoneampicillin + sulbactampiperacillin + tazobactam
03
Conditions
post-operative wound infection (SSI)
Beyond the preview
Go deeper on NCT03560232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560232.